Document is current
Any future updates will be listed below
-
Authors
Danno, Daisuke https://orcid.org/0000-0003-3737-4754
Suzuki, Shiho https://orcid.org/0009-0007-7430-2078
Takizawa, Tsubasa https://orcid.org/0000-0003-2605-7200
Ishii, Ryotaro https://orcid.org/0000-0002-6976-1081
Hamakawa, Masayuki https://orcid.org/0000-0003-1823-8394
Tanizawa, Yoshinori https://orcid.org/0000-0002-5014-2483
Osaga, Satoshi https://orcid.org/0000-0003-4459-2469
Komori, Mika https://orcid.org/0000-0003-1887-1296
-
Funding
Funding for this research was provided by:
Eli Lilly Japan
- License Information
-
More Information
Article History
Received: 10 October 2024
Accepted: 21 November 2024
First Online: 21 December 2024
Declarations
:
: Daisuke Danno serves on the advisory boards of and received speaker honoraria from Amgen K.K., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K. and Otsuka Pharmaceutical Co. Ltd. Shiho Suzuki received speaker honoraria from Amgen K.K., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co. Ltd. Tsubasa Takizawa is a consultant/advisor and/or serves on an advisory board for Eli Lilly Japan K.K., Otsuka Pharmaceutical Co. Ltd., Amgen K.K., Pfizer Japan Inc., and Teijin Pharma Ltd. He received speaker honoraria from Eli Lilly Japan K.K., Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Amgen K.K., Kowa Company, Ltd., Kyowa Kirin Co. Ltd., Eisai Co. Ltd., UCB Japan Co. Ltd., Takeda Pharmaceutical Company Ltd., and Santen Pharmaceutical, a grant from Pfizer Japan Inc., and research funding from Eli Lilly Japan K.K. and Tsumura & Co. outside the submitted work. Ryotaro Ishii received consulting fees from Amgen K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co. Ltd., and Otsuka Pharmaceutical Co. Ltd; speaker honoraria from Amgen K.K., Daiichi Sankyo Co. Ltd., and Otsuka Pharmaceutical Co. Ltd. Masayuki Hamakawa is an employee of Social Survey Research Information Co., Ltd. Data collection and statistical analyses in this study were performed by Social Survey Research Information Co., Ltd. and sponsored by Eli Lilly Japan K.K. Yoshinori Tanizawa, Satoshi Osaga, and Mika Komori are employees of Eli Lilly Japan K.K. and may own stock/stock options of Eli Lilly and Company.
: The Medical Corporation TOUKEIKAI Kitamachi Clinic ethics committee approved this study (number BGQ09531) on April 19, 2023. This study was conducted in accordance with ethical principles originating from the Declaration of Helsinki and that were consistent with Good Pharmacoepidemiology Practices. All survey respondents provided electronic informed consent, and all data were anonymized before analysis.
